A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

NCT05538624 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision to close study

Conditions

Neoplasm, Ovarian
Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer
Adenocarcinoma Ovary
Serous Adenocarcinoma of Ovary
Serous Adenocarcinoma of Primary Peritoneum
Primary Peritoneal Carcinoma
High Grade Serous Adenocarcinoma

Interventions

DRUG: AVB-001 (Dose Escalation Phase)
DRUG: AVB-001 (Dose Expansion Phase)

Sponsor

Avenge Bio, Inc